Rahul Banerjee: Largest RW Experience with Teclistamab
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post on X:
“Now in Blood Cancer Discovery: Largest RW experience with teclistamab ever!
Of 509 US patients (88% TEC-1), ORR 53% and ≥VGPR 45%. mDOR 16 mo if ≥VGPR.
I like ≥VGPR focus, i.e. Multiple Myeloma M-spike not 0 yet. When occurs, DOR similar for BCMA-naive vs exposed more 9 than one month ago!”
Title: Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium
Authors: Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, Rahul Banerjee, Andrew J. Cowan, Aimaz Afrough, Larry D. Anderson, Alex Lieberman-Cribbin, Gurbakhash Kaur, Anmol Goyal, Shebli Atrash, Christopher J. Ferreri, Peter M. Voorhees, Oren Pasvolsky, Hans C. Lee, Krina K. Patel, Kelley L. Julian, Peter A. Forsberg, Megan M. Herr, Saurabh Chhabra, Ricardo D. Parrondo, Yi Lin, Anna Chen, Sandra P. Susanibar-Adaniya, Jack Khouri, Shahzad Raza, Faiz Anwer, Mariola Vazquez-Martinez, Omar Castaneda Puglianini, Douglas W. Sborov, James A. Davis, Adriana Rossi, Leyla Shune, Jenny Bhurtel, Wei-Ting Hwang, Doris K. Hansen, Surbhi Sidana, Alfred L. Garfall, Shambavi Richard
Read The Full Article at Blood Cancer Discovery.
More posts featuring Rahul Banerjee.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023